{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:40:22Z","timestamp":1790628022511,"version":"4.1.0"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.bone.2015.04.026","type":"journal-article","created":{"date-parts":[[2015,4,25]],"date-time":"2015-04-25T12:48:53Z","timestamp":1429966133000},"page":"93-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":151,"special_numbering":"C","title":["Effects of diabetes drugs on the skeleton"],"prefix":"10.1016","volume":"82","author":[{"given":"Christian","family":"Meier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann V.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Lecka-Czernik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2015.04.026_bb0005","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00198-006-0253-4","article-title":"Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes\u2014a meta-analysis","volume":"18","author":"Vestergaard","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2015.04.026_bb0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/aje\/kwm106","article-title":"Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture","volume":"166","author":"Janghorbani","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.bone.2015.04.026_bb0015","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1001\/jama.2011.715","article-title":"Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes","volume":"305","author":"Schwartz","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2015.04.026_bb0020","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1002\/jbmr.1759","article-title":"Type 2 diabetes and bone","volume":"27","author":"Leslie","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2015.04.026_bb0025","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1210\/endo-124-2-565","article-title":"Bone mineral homeostasis in spontaneously diabetic BB rats. I. Abnormal vitamin D metabolism and impaired active intestinal calcium absorption","volume":"124","author":"Nyomba","year":"1989","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2015.04.026_bb0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S8756-3282(00)00426-9","article-title":"Glucose-induced inhibition of in vitro bone mineralization","volume":"28","author":"Balint","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.bone.2015.04.026_bb0035","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1007\/s00198-006-0155-5","article-title":"Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN\/Kob rats","volume":"17","author":"Saito","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2015.04.026_bb0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S8756-3282(00)00434-8","article-title":"Influence of nonenzymatic glycation on biomechanical properties of cortical bone","volume":"28","author":"Vashishth","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.bone.2015.04.026_bb0045","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.2337\/dc09-0901","article-title":"Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes","volume":"32","author":"Yamamoto","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bone.2015.04.026_bb0050","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1210\/jc.2008-2498","article-title":"Pentosidine and increased fracture risk in older adults with type 2 diabetes","volume":"94","author":"Schwartz","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2015.04.026_bb0055","article-title":"Biochemical bone turnover markers in diabetes mellitus\u2014a systematic review","author":"Starup-Linde","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2015.04.026_bb0060","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2337\/diab.44.7.775","article-title":"Bone loss and bone turnover in diabetes","volume":"44","author":"Krakauer","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.bone.2015.04.026_bb0065","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1359\/JBMR.050514","article-title":"Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone","volume":"20","author":"Kume","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2015.04.026_bb0070","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1196\/annals.1433.044","article-title":"Pentosidine effects on human osteoblasts in vitro","volume":"1126","author":"Sanguineti","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bone.2015.04.026_bb0075","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.biocel.2003.09.006","article-title":"Advanced glycation endproducts interefere with integrin-mediated osteoblastic attachment to a type-I collagen matrix","volume":"36","author":"McCarthy","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.bone.2015.04.026_bb0080","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1210\/jc.2011-2958","article-title":"Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes","volume":"97","author":"Gennari","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2015.04.026_bb0085","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1210\/jc.2012-1901","article-title":"Sclerostin levels associated with inhibition of the Wnt\/beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus","volume":"97","author":"Gaudio","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2015.04.026_bb0090","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00198-014-2988-7","article-title":"Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures","volume":"26","author":"Heilmeier","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2015.04.026_bb0095","doi-asserted-by":"crossref","first-page":"11410","DOI":"10.1074\/jbc.M113.541458","article-title":"Hyperglycemia diverts dividing osteoblastic precursor cells to an adipogenic pathway and induces synthesis of a hyaluronan matrix that is adhesive for monocytes","volume":"289","author":"Wang","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2015.04.026_bb0100","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.2462","article-title":"Glycated hemoglobin level and risk of hip fracture in older people with type 2 diabetes: a competing risk analysis of Taiwan Diabetes Cohort Study","author":"Li","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2015.04.026_bb0105","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2337\/diacare.24.7.1192","article-title":"Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women","volume":"24","author":"Nicodemus","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bone.2015.04.026_bb0110","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2337\/dc12-1188","article-title":"High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study","volume":"36","author":"Oei","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bone.2015.04.026_bb0115","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2337\/dc12-1168","article-title":"Diabetes and risk of fracture-related hospitalization: the Atherosclerosis Risk in Communities Study","volume":"36","author":"Schneider","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bone.2015.04.026_bb0120","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00223-013-9703-0","article-title":"Intensive glycemic control and thiazolidinedione use: effects on cortical and trabecular bone at the radius and tibia","volume":"92","author":"Schwartz","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2015.04.026_bb0125","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bone.2015.04.026_bb0130","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2015.04.026_bb0135","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.bone.2010.12.003","article-title":"Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2","volume":"48","author":"Jang","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2015.04.026_bb0140","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1002\/jcb.23206","article-title":"Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats","volume":"112","author":"Mai","year":"2011","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.bone.2015.04.026_bb0145","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ejphar.2011.07.033","article-title":"Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats","volume":"668","author":"Sedlinsky","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bone.2015.04.026_bb0150","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc07-2270","article-title":"Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from a Diabetes Outcome Progression Trial (ADOPT)","volume":"31","author":"Kahn","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bone.2015.04.026_bb0155","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1210\/jc.2009-0572","article-title":"Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes","volume":"95","author":"Zinman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2015.04.026_bb0160","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1359\/jbmr.080323","article-title":"Fracture risk in type 2 diabetes: update of a population-based study","volume":"23","author":"Melton","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2015.04.026_bb0165","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00223-008-9195-5","article-title":"Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes","volume":"84","author":"Vestergaard","year":"2009","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2015.04.026_bb0170","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archinte.168.8.820","article-title":"Use of thiazolidinediones and fracture risk","volume":"168","author":"Meier","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.bone.2015.04.026_bb0175","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2337\/dc07-1736","article-title":"Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case\u2013control study","volume":"31","author":"Monami","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bone.2015.04.026_bb0180","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s00774-010-0160-9","article-title":"Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus","volume":"28","author":"Kanazawa","year":"2010","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.bone.2015.04.026_bb0185","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1210\/jc.2009-2638","article-title":"Thiazolidinediones and fractures: evidence from translating research into action for diabetes","volume":"95","author":"Bilik","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2015.04.026_bb0190","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1007\/s00125-012-2668-0","article-title":"Scottish Diabetes Research Network Epidemiology G. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs","volume":"55","author":"Colhoun","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.bone.2015.04.026_bb0195","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00125-014-3289-6","article-title":"Fracture risk in diabetic elderly men: the MrOS study","volume":"57","author":"Napoli","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.bone.2015.04.026_bb0200","doi-asserted-by":"crossref","first-page":"b4731","DOI":"10.1136\/bmj.b4731","article-title":"Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database","volume":"339","author":"Tzoulaki","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.bone.2015.04.026_bb0205","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2015.04.026_bb0210","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2015.04.026_bb0215","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2015.04.026_bb0220","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-Jarvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2015.04.026_bb0225","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00198-007-0477-y","article-title":"Skeletal consequences of thiazolidinedione therapy","volume":"19","author":"Grey","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2015.04.026_bb0230","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s11914-010-0027-y","article-title":"Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis","volume":"8","author":"Lecka-Czernik","year":"2010","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.bone.2015.04.026_bb0235","series-title":"Letter to health care providers","article-title":"Observation of an increased incidence of fractures in female patients who received long-term treatment with Actos (pioglitazone HCl) tablets for type 2 diabetes mellitus","author":"Takeda","year":"2007"},{"key":"10.1016\/j.bone.2015.04.026_bb0240","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1503\/cmaj.080486","article-title":"Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis","volume":"180","author":"Loke","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.bone.2015.04.026_bb0245","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.08.010","article-title":"Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials","volume":"68","author":"Zhu","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2015.04.026_bb0250","doi-asserted-by":"crossref","first-page":"e1000154","DOI":"10.1371\/journal.pmed.1000154","article-title":"The risk of fractures associated with thiazolidinediones: a self-controlled case-series study","volume":"6","author":"Douglas","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.bone.2015.04.026_bb0255","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2006-2646","article-title":"The peroxisome proliferator-activated receptor-{gamma} agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial","volume":"92","author":"Grey","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2015.04.026_bb0260","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1210\/jc.2007-2249","article-title":"Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial","volume":"93","author":"Glintborg","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2015.04.026_bb0265","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2265.2010.03784.x","article-title":"Effects of rosiglitazone on bone mineral density and remodelling parameters in postmenopausal diabetic women: a 2-year follow-up study","volume":"73","author":"Berberoglu","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.bone.2015.04.026_bb0270","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1463-1326.2011.01461.x","volume":"13","author":"Borges","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.bone.2015.04.026_bb0275","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1210\/jc.2012-4018","article-title":"Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus","volume":"98","author":"Bilezikian","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2015.04.026_bb0280","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1530\/EJE-13-0793","article-title":"The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial","volume":"170","author":"Grey","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.bone.2015.04.026_bb0285","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1210\/jc.2010-2077","article-title":"Rosiglitazone decreases bone mass and bone marrow fat","volume":"96","author":"Harslof","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2015.04.026_bb0290","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1210\/jc.2012-4096","article-title":"Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study","volume":"98","author":"Bone","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2015.04.026_bb0295","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00223-010-9352-5","article-title":"The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial","volume":"86","author":"Gruntmanis","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2015.04.026_bb0300","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1530\/EJE-11-1061","article-title":"Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus","volume":"166","author":"van Lierop","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.bone.2015.04.026_bb0305","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1530\/EJE-11-1061","article-title":"Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus","volume":"166","author":"van Lierop","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.bone.2015.04.026_bb0310","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPARgamma signaling and metabolism: the good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.bone.2015.04.026_bb0315","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1210\/endo.143.6.8834","article-title":"Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation","volume":"143","author":"Lecka-Czernik","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2015.04.026_bb0320","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jcb.21994","article-title":"PPAR\u03b32 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells","volume":"106","author":"Shockley","year":"2009","journal-title":"J Cell Biochem"},{"issue":"6","key":"10.1016\/j.bone.2015.04.026_bb0325","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1210\/en.2006-1587","article-title":"Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone","volume":"148","author":"Lazarenko","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2015.04.026_bb0330","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/nm1672","article-title":"PPAR-gamma regulates osteoclastogenesis in mice","volume":"13","author":"Wan","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.bone.2015.04.026_bb0335","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.cmet.2010.04.015","article-title":"PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss","volume":"11","author":"Wei","year":"2010","journal-title":"Cell Metab"},{"key":"10.1016\/j.bone.2015.04.026_bb0340","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/stem.1455","article-title":"Osteoblast-targeted suppression of PPARgamma increases osteogenesis through activation of mTOR signaling","volume":"31","author":"Sun","year":"2013","journal-title":"Stem Cells"},{"key":"10.1016\/j.bone.2015.04.026_bb0345","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1210\/en.2003-0746","article-title":"Bone is a target for the antidiabetic compound rosiglitazone","volume":"145","author":"Rzonca","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2015.04.026_bb0350","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00223-004-0224-8","article-title":"Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone)","volume":"75","author":"Sottile","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2015.04.026_bb0355","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1677\/joe.1.05723","article-title":"Rosiglitazone impacts negatively on bone by promoting osteoblast\/osteocyte apoptosis","volume":"183","author":"Soroceanu","year":"2004","journal-title":"J Endocrinol"},{"key":"10.1016\/j.bone.2015.04.026_bb0360","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/sj.embor.7400254","article-title":"Enhanced bone formation in lipodystrophic PPARgamma(hyp\/hyp) mice relocates haematopoiesis to the spleen","volume":"5","author":"Cock","year":"2004","journal-title":"EMBO Rep"},{"key":"10.1016\/j.bone.2015.04.026_bb0365","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1210\/en.2004-0735","article-title":"Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation","volume":"146","author":"Ali","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2015.04.026_bb0370","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1172\/JCI200419900","article-title":"PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors","volume":"113","author":"Akune","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2015.04.026_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2015.01.045","article-title":"Impact of targeted PPARgamma disruption on bone remodeling","author":"Cao","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.bone.2015.04.026_bb0380","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1210\/en.2006-1121","article-title":"Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo","volume":"148","author":"Lecka-Czernik","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2015.04.026_bb0385","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1474-9728.2004.00127.x","article-title":"Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma\/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta\/BMP signaling pathways","volume":"3","author":"Moerman","year":"2004","journal-title":"Aging Cell"},{"key":"10.1016\/j.bone.2015.04.026_bb0390","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","article-title":"Fat and beyond: the diverse biology of PPARgamma","volume":"77","author":"Tontonoz","year":"2008","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.bone.2015.04.026_bb0395","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature10383","article-title":"Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation","volume":"477","author":"Choi","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bone.2015.04.026_bb0400","doi-asserted-by":"crossref","first-page":"e51746","DOI":"10.1371\/journal.pone.0051746","article-title":"Beta-catenin directly sequesters adipocytic and insulin sensitizing activities but not osteoblastic activity of PPARgamma2 in marrow mesenchymal stem cells","volume":"7","author":"Rahman","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bone.2015.04.026_bb0405","doi-asserted-by":"crossref","first-page":"42911","DOI":"10.1074\/jbc.M111.311662","article-title":"Protein phosphatase 5 mediates lipid metabolism through reciprocal control of glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma (PPARgamma)","volume":"286","author":"Hinds","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2015.04.026_bb0410","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1210\/me.2014-1023","article-title":"FKBP51 reciprocally regulates GRalpha and PPARgamma activation via the Akt-p38 pathway","volume":"28","author":"Stechschulte","year":"2014","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.bone.2015.04.026_bb0415","doi-asserted-by":"crossref","first-page":"267S","DOI":"10.3945\/ajcn.2009.28449E","article-title":"Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation","volume":"91","author":"Higgins","year":"2010","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.bone.2015.04.026_bb0420","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bone.2005.07.008","article-title":"Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat","volume":"38","author":"Lazarenko","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.bone.2015.04.026_bb0425","doi-asserted-by":"crossref","first-page":"E552","DOI":"10.1152\/ajpendo.00569.2011","article-title":"Selective PPARgamma modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice","volume":"302","author":"Lee","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.bone.2015.04.026_bb0430","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/jbmr.2364","article-title":"An insulin-sensitizing thiazolidinedione, which minimally activates PPAR, does not cause bone loss","volume":"30","author":"Fukunaga","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2015.04.026_bb0435","doi-asserted-by":"crossref","first-page":"e96323","DOI":"10.1371\/journal.pone.0096323","article-title":"Partial agonist, telmisartan, maintains PPARgamma serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass","volume":"9","author":"Kolli","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bone.2015.04.026_bb0440","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bone.2015.04.026_bb0445","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s00125-005-1786-3","article-title":"Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk","volume":"48","author":"Vestergaard","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.bone.2015.04.026_bb0450","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2015.04.026_bb0455","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s12018-012-9129-7","article-title":"Safety of anti-diabetic therapies on bone","volume":"11","author":"Lecka-Czernik","year":"2013","journal-title":"Clin Rev Bone Miner Metab"},{"key":"10.1016\/j.bone.2015.04.026_bb0460","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2015.04.026_bb0465","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40266-013-0081-0","article-title":"Sulfonylureas and risk of falls and fractures: a systematic review","volume":"30","author":"Lapane","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.bone.2015.04.026_bb0470","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.bone.2015.04.026_bb0475","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/apt.12092","article-title":"Review article: a comparison of glucagon-like peptides 1 and 2","volume":"37","author":"Janssen","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bone.2015.04.026_bb0480","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1146\/annurev-physiol-021113-170317","article-title":"Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2","volume":"76","author":"Drucker","year":"2014","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.bone.2015.04.026_bb0485","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1055\/s-2004-826160","article-title":"Circulation and degradation of GIP and GLP-1","volume":"36","author":"Deacon","year":"2004","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.bone.2015.04.026_bb0490","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/edrv.20.6.0385","article-title":"The glucagon-like peptides","volume":"20","author":"Kieffer","year":"1999","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bone.2015.04.026_bb0495","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bone.2015.04.026_bb0500","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bone.2006.09.025","article-title":"Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women","volume":"40","author":"Henriksen","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bone.2015.04.026_bb0505","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.bone.2007.01.007","article-title":"Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass","volume":"40","author":"Xie","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bone.2015.04.026_bb0510","doi-asserted-by":"crossref","first-page":"E543","DOI":"10.1152\/ajpendo.00364.2006","article-title":"Effects of glucose-dependent insulinotropic peptide on osteoclast function","volume":"292","author":"Zhong","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.bone.2015.04.026_bb0515","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1210\/en.2007-1292","article-title":"The murine glucagon-like peptide-1 receptor is essential for control of bone resorption","volume":"149","author":"Yamada","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2015.04.026_bb0520","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.abb.2010.06.020","article-title":"Feeding and bone","volume":"503","author":"Walsh","year":"2010","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.bone.2015.04.026_bb0525","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bone.2003.09.009","article-title":"Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2","volume":"34","author":"Henriksen","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bone.2015.04.026_bb0530","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.bone.2009.07.008","article-title":"Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD","volume":"45","author":"Henriksen","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bone.2015.04.026_bb0535","first-page":"401","article-title":"Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes","volume":"4","author":"Nielsen","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.bone.2015.04.026_bb0540","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/jbmr.1898","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats","volume":"28","author":"Ma","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2015.04.026_bb0545","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.lfs.2013.01.001","article-title":"Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST\/sclerostin in osteocytes","volume":"92","author":"Kim","year":"2013","journal-title":"Life Sci"},{"key":"10.1016\/j.bone.2015.04.026_bb0550","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1463-1326.2010.01355.x","article-title":"Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes","volume":"13","author":"Bunck","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bone.2015.04.026_bb0555","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/1753-0407.12102","article-title":"Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials","volume":"6","author":"Mabilleau","year":"2014","journal-title":"J Diabetes"},{"key":"10.1016\/j.bone.2015.04.026_bb0560","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12020-014-0361-4","article-title":"Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials","volume":"48","author":"Su","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.bone.2015.04.026_bb0565","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12020-014-0461-1","article-title":"Use of GLP-1 mimetic in type 2 diabetes mellitus: is it the end of fragility fractures?","volume":"48","author":"Mabilleau","year":"2015","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.bone.2015.04.026_bb0570","doi-asserted-by":"crossref","first-page":"E447","DOI":"10.1152\/ajpendo.00217.2014","article-title":"DPP4 inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats","volume":"307","author":"Glorie","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.bone.2015.04.026_bb0575","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1753-0407.2011.00168.x","article-title":"Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients","volume":"4","author":"Bunck","year":"2012","journal-title":"J Diabetes"},{"key":"10.1016\/j.bone.2015.04.026_bb0580","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2337\/dc11-1099","article-title":"Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials","volume":"34","author":"Monami","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bone.2015.04.026_bb0585","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bone.2014.07.030","article-title":"Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture","volume":"68","author":"Driessen","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2015.04.026_bb0590","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/dom.12077","article-title":"Antidiabetic therapy effects on bone metabolism and fracture risk","volume":"15","author":"Montagnani","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bone.2015.04.026_bb0595","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2015.04.026_bb0600","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bone.2015.04.026_bb0605","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition\u2014a novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bone.2015.04.026_bb0610","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial","volume":"34","author":"Nauck","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bone.2015.04.026_bb0615","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bone.2015.04.026_bb0620","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1463-1326.2012.01630.x","article-title":"Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin","volume":"14","author":"Ljunggren","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bone.2015.04.026_bb0625","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.bone.2015.04.026_bb0630","series-title":"Endocrinology and Metabolic Drugs Advisory Committee Meeting","article-title":"Canagliflozin: clinical efficacy and safety","author":"Kwohn","year":"2013"},{"key":"10.1016\/j.bone.2015.04.026_bb0635","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","article-title":"Possible adverse effects of SGLT2 inhibitors on bone","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.bone.2015.04.026_bb0640","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrendo.2011.218","article-title":"Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism","volume":"8","author":"Quarles","year":"2012","journal-title":"Nat Rev Endocrinol"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328215001398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328215001398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T23:28:45Z","timestamp":1566602925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328215001398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":128,"alternative-id":["S8756328215001398"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2015.04.026","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of diabetes drugs on the skeleton","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2015.04.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}